Cutaneous phosphorylated alpha-synuclein deposition increased over time and correlated with objective orthostatic hypotension and autonomic symptom burden in early synucleinopathy, and may serve as a minimally invasive tool to support diagnosis, monitor progression, and stratify clinical trial participants.
P. Trujillo, Leah G. Mann, B. Bellaire et al.· Clinical Autonomic Research· 1 citation
Introduction The neurodegenerative disorders characterized by deposition of phosphorylated alpha-synuclein (P-SYN) include Parkinson’s disease (PD), multiple system atrophy (MSA) and dementia with Lewy bodies (DLB). Diagnosis of synucleinopathies in clinical practice has been enhanced by recent updates to diagnostic gu...
T. Levine, R. Freeman, N. Murray et al.· Frontiers in Neurology· 0 citations
The PP-MSA criteria demonstrate high sensitivity but limited specificity in patients with PAF and a stricter olfactory threshold improves diagnostic performance and may enhance cohort enrichment for clinical trials.
Patricio Millar Vernetti, J. Palma, I. Biaggioni et al.· Movement Disorders· 1 citation
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.